Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574132 · ClinicalTrials.gov registry record · Phase 3
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
A Phase 3 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,331
- Enrollment target
NCT00574132: Completed Phase 3 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT00574132 is a Phase 3 study that has completed, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 1,331 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00574132, a Phase 3 study, has completed, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,331 participants
- Enrollment target
Study Summary
This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 230 study sites in the US and Canada and up to 35 sites outside of North America will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years. Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Interventions
- DRUG Placebo Control
- DRUG Bapineuzumab 0.5 mg/kg
- DRUG Bapineuzumab 1.0 m/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,331 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574132
The ClinicalTrials.gov registry entry for NCT00574132 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Control is the first listed.
NCT00574132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574132 about?
NCT00574132 is a clinical study titled "Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)". This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 230 study sites in the US and Canada and up to 35 sites outside of North America will be involved. Pat...
What is the current status of trial NCT00574132?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,331 participants. The study started on 2007-12. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00574132?
The interventions under investigation include: Placebo Control (DRUG), Bapineuzumab 0.5 mg/kg (DRUG), Bapineuzumab 1.0 m/kg (DRUG).
Who is sponsoring clinical trial NCT00574132?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.